{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:20:13Z","timestamp":1794352813089,"version":"4.9.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.euo.2024.09.011","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T21:39:53Z","timestamp":1727559593000},"page":"234-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical Implementation of Urinary Biomarkers for Surveillance of Non\u2013muscle-invasive Bladder Cancer (NMIBC): Considerations from the European Association of Urology NMIBC Guideline Panel"],"prefix":"10.1016","volume":"8","author":[{"given":"Fredrik","family":"Liedberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.09.011_b0005","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bju.15194","article-title":"Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study","volume":"127","author":"Gontero","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.09.011_b0010","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cyt.13407","article-title":"Impact of implementing the first edition of the Paris system for reporting: a systematic review and meta-analysis","volume":"35","author":"Farahani","year":"2024","journal-title":"Cytopathology"},{"key":"10.1016\/j.euo.2024.09.011_b0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2024.01.004","article-title":"The elusive horizon: biomarkers in urothelial carcinoma","volume":"85","author":"Linscott","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.011_b0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.juro.2009.08.150","article-title":"Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial","volume":"183","author":"van der Aa","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.09.011_b0025","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/bmj.329.7458.168","article-title":"Diagnostic tests 4: likelihood ratios","volume":"329","author":"Deeks","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2024.09.011_b0030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eursup.2009.06.008","article-title":"Cytology and urinary markers for the diagnosis of bladder cancer","volume":"8","author":"van Rhijn","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.euo.2024.09.011_b0035","doi-asserted-by":"crossref","unstructured":"Wolff I, Kravchuk AP, Wirtz RM, et al. Real-world performance of Uromonitor\u00ae in urothelial bladder cancer detection: a multicentric trial. BJU Int, in press. https:\/\/doi.org\/10.1111\/bju.16450.","DOI":"10.1111\/bju.16450"},{"key":"10.1016\/j.euo.2024.09.011_b0040","first-page":"33","article-title":"Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial","volume":"172","author":"Olsen","year":"1995","journal-title":"Scand J Urol Nephrol Suppl."},{"key":"10.1016\/j.euo.2024.09.011_b0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.euros.2024.02.018","volume":"63","author":"Schroeck","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2024.09.011_b0050","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1007\/s00345-019-02728-4","article-title":"Patients choose certainty over burden in bladder cancer surveillance","volume":"37","author":"van Osch","year":"2019","journal-title":"World J Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:51:39Z","timestamp":1744869099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2588931124002219"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.09.011","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Implementation of Urinary Biomarkers for Surveillance of Non\u2013muscle-invasive Bladder Cancer (NMIBC): Considerations from the European Association of Urology NMIBC Guideline Panel","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}